Loading company…
TiCARos develops CAR-T therapies for cancer treatment.
Founded in 2018 and based in Seoul, South Korea, TiCARos develops immuno-oncology treatments using CAR-T therapy. It has research partnerships with the National Cancer Center and Seoul National University Hospital. The company uses a closed, automated CAR-T production system. In March 2026, it raised KRW 20.8 billion in Series D funding from Kiwoom Securities, iM Investment Partners and SJ Investment Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in